Volume 10, Issue 04, April 2024,
Publish Date: 29-04-2024
Doi https://doi.org/10.55640/ijmsdh-10-04-32

International Journal of Medical Science and Dental Health (Open Access)

HEPATIC ENZYMES AND PROTEINS AS PROGNOSTIC FACTORS IN LIVER DISEASE MANAGEMENT

W T. H. AL-SHAMMARI[1], REAM ISMAIL ABED[2], HANAN HUSSEIN ALI[3]

[1,2,3] Al-Karkh University of Science

ABSTRACT

Therefore, an article reviewing a hepatic enzyme/protein prognosis in liver disease studies is presented. Hepatocytic enzymes such as Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) being highly contributory indicators demonstrate mild to severe active liver inflammation and damage. Compared to this, it is worth noting that the so-called proteins which are referred to as albumin and alpha-fetoprotein (AFP) provide data on liver function and the severity of the disease, mainly in HCC (hepatocellular carcinoma).

The review clarifies the role of these biomarkers in clinical practice attributing them to various indicators such as diagnosis, disease differentiation, treatment monitoring, and prognosis assessment. Difficulties, including variability, sensitivity problems, and complexity on the interpretation of results, are pointed out, showing the necessity of enhanced diagnosis tehnologies and personalized medicine strategies.

The future of liver disease management concentrates on biomarker identification, better diagnostic equipment, embedding artificial intelligence, personized treatment, and involving authorities. The objective is to improve diagnostic accuracy, guid treatment outcomes, and apply ethics in genetic information.

In summary, these pioneering technologies have the potential to make a substantial contribution to the level of liver disease treatment, provided that we address the connected problems, which will consequently result in better patients' outcomes and quality of care.

INTRODUCTION

Liver diseases which cover a wide spectrum of conditions from hepatitis to cirrhosis and liver cancer at all are one of the major population health issues across the globe. Prediction of acute and unknown conditions crucial for efficient detection and treatment are based on early and timely availing of the disease progression and outcomes. Along with this, prognostic factors are seen as being very important in this regard, with data on what the likely course of disease can offer, thus informing treatments and clinical decision making [1-4].

Liver specific prognostic factors in the management of liver diseases include above all determinants such as hepatocellular enzymes and proteins. The genetic markers of hepatic toxicity are the cornerstone of danger history of these liver conditions. The enzymes present in liver - specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST) - are the most frequently used markers for the determination of liver function and damage. Therefore, ESR and proteins such as albumin and alpha-fetoprotein are indicators of the liver status as well as the amount of damage [5].

One of the main tasks of this review article is to explore the function of hepatic enzymes and proteins as clinical markers in liver disease. Through the evaluation of their diagnostic value, mode of action, and the most outstanding studies on the topic, this review tries to update professionals that are involved in the fight against hepatic impairment on how to manage effectively such a problem. Meanwhile, by demonstrating the current existing applications plus the future developments in the sector, exploration will also be done.

Role of Hepatic Enzymes in Liver Disease

Hepatic enzymes are a type of biochemical marker that are involved in liver pathophysiology through various mechanisms. These enzymes often determine the hepatic condition and their management. These hepatocellular enzymes, which seep into the bloodstream due to a liver damage, comprise the liver cells, thus, offering very important pieces of information on the state and the kind of injury [6-9].

Overview of Key Hepatic Enzymes

The most important hepatic enzymes include [10]:

- Alanine Aminotransferase (ALT): Primarily found in the liver, elevated levels of ALT in the blood often suggest liver damage.
- Aspartate Aminotransferase (AST): Although present in various tissues including heart and muscles, AST is also a marker for liver damage when elevated disproportionately.
- Alkaline Phosphatase (ALP): Rise cases in bile duct conditions and also the liver.
- Gamma-glutamyl Transferase (GGT): Usually used to envision liver ailment and difference between liver and bone illness.

Table 1 *(Comprehensive Overview of Key Hepatic Enzymes in Liver Disease Diagnosis and Management)*

Enzyme	Primary Location	Function in Liver	Significance of Elevation	Typical Diseases Associated	Diagnostic Value
Alanine Aminotransferase (ALT)	Liver	Involved in amino acid metabolism; converts alanine and α-ketoglutarate into pyruvate and glutamate.	Often indicates liver cell injury or inflammation.	Viral hepatitis, fatty liver disease, liver injury.	High specificity to liver damage; used to detect and monitor disease progress.

Aspartate Aminotransferase (AST)	Liver, heart, muscles, kidneys	Participates in the conversion of aspartate and α-ketoglutarate to oxaloacetate and glutamate.	Can indicate liver damage but less liver-specific than ALT.	Hepatitis, cirrhosis, liver injury, muscle diseases.	Often measured alongside ALT to assess liver injury; AST/ALT ratio can indicate specific types of liver disease.
Alkaline Phosphatase (ALP)	Liver, bone, kidney, intestine	Important for breaking down proteins; higher activity in bile duct cells.	High levels may indicate bile duct obstruction or liver damage.	Cholestasis, bile duct obstruction, liver cancer.	Useful in diagnosing cholestatic conditions of the liver.
Gamma-glutamyl Transferase (GGT)	Liver, kidney, pancreas	Involved in the transfer of amino acids across the cellular membrane and in glutathione metabolism.	Elevated levels can indicate liver disease, bile duct issues, or excessive alcohol consumption.	Biliary obstruction, alcoholic liver disease, hepatocellular damage.	Particularly valuable for diagnosing biliary diseases and distinguishing between hepatic and bone disease causes of elevated ALP.

Mechanisms and Pathways Affected by Hepatic Enzymes

Hepatic enzymes are involved in numerous metabolic pathways essential for liver function, including:

- **Amino Acid Metabolism:** ALT and AST are involved in the transamination process, crucial for synthesizing non-essential amino acids [11].
- **Glucose Metabolism:** Enzymes help in gluconeogenesis, a process where glucose is produced from non-carbohydrate sources [12].
- **Detoxification:** Liver enzymes play a key role in detoxifying substances, ensuring harmful toxins are converted into less harmful products before being excreted [13].

This process of quantification gives the chance to evaluate the metabolic state of the organ of the digestion. On the other hand, marked enzyme increase might imply hepatic inflammation, necrosis, or cholestasis, and the enzyme in question along with magnitude of increase determines the cause.

Clinical Significance of Hepatic Enzyme Levels

Elevated hepatic enzyme levels can indicate various forms of liver disease [14]:

- **Hepatitis:** Viral or alcoholic hepatitis typically show elevated ALT and AST levels.
- **Fatty Liver Disease:** Characterized by moderate elevations in ALT and AST.
- **Cirrhosis:** Later stages may show altered levels due to significant liver damage.

Protein Markers in Liver Disease

Protein days satisfy the purpose of evaluation of the status of the hepatitis disease and its progression. They can provide either functional trend of liver cells or give hint for the outcome of liver diseases and then organize a quantitative assessment of the treatment plan if needed [15].

Types of Hepatic Proteins and Their Functions

Albumin [16, 17].

- **Function:** Maintains oncotic pressure and transports hormones, vitamins, and drugs.
- **Clinical Significance:** Low levels can indicate chronic liver disease or cirrhosis, reflecting decreased synthetic function of the liver.

Alpha-fetoprotein (AFP) [18].

- **Function:** Produced in the liver of developing embryos, its levels drop significantly after birth.
- **Clinical Significance:** Elevated levels are often associated with hepatocellular carcinoma (HCC) and, to a lesser extent, with germ cell tumors of the ovary and testis.

Fibrinogen [19].

- **Function:** Plays a critical role in blood clotting.
- **Clinical Significance:** Reduced levels may be seen in severe liver disease due to impaired synthesis.

Protein Biomarkers for Disease Progression and Outcome Prediction

C-reactive protein (CRP) [20].

- **Role:** An acute-phase reactant used to measure inflammation.
- **Utility in Liver Diseases:** Elevated in inflammatory conditions; assists in distinguishing between inflammatory and non-inflammatory diseases.

Ceruloplasmin [21].

- Role: Essential for iron metabolism; carries more than 95% of the total copper in healthy human plasma.
- Utility in Liver Diseases: Levels are decreased in Wilson's disease, a genetic disorder affecting copper metabolism in the liver.

Clinical Applications of Protein Markers

These proteins not only help in diagnosing liver conditions but are also pivotal in assessing disease severity and prognosis. For instance:

- **Albumin levels** are used to calculate the Child-Pugh score, a prognostic indicator for chronic liver disease and cirrhosis that predicts survival.
- **AFP levels** are part of diagnostic criteria for HCC and are used to monitor treatment response or recurrence after therapy.

Table 2 *(Key Protein Markers and Their Roles in the Diagnosis and Management of Liver Disease.)*

Protein Marker	Primary Function	Clinical Significance	Associated Liver Conditions	Role in Disease Management	Typical Diagnostic Usage
Albumin	Maintains oncotic pressure and transports various substances.	Indicator of synthetic liver function; low levels suggest chronic liver disease.	Cirrhosis, chronic hepatitis, liver failure.	Used to calculate Child-Pugh score for assessing disease severity and prognosis.	Monitoring liver function and nutritional status.
Alpha-fetoprotein (AFP)	Embryonic liver protein, decreases after birth.	Elevated levels suggest hepatocellular carcinoma (HCC).	Hepatocellular carcinoma, liver regeneration post-injury.	Screening for HCC, monitoring treatment response or recurrence.	Diagnostic marker in liver cancer protocols.
Fibrinogen	Essential for blood clot formation.	Decreased production indicates impaired liver synthesis capacity.	Advanced liver disease, cirrhosis.	Assessing liver synthetic function, especially in severe liver pathology.	Part of liver function tests to evaluate coagulation status.
C-reactive protein (CRP)	Acute phase reactant indicating inflammation.	Elevated levels can indicate inflammatory liver diseases.	Acute hepatitis, alcoholic hepatitis, liver abscesses.	Differentiating inflammatory from non-inflammatory liver conditions.	Used in conjunction with other tests to assess liver inflammation.
Ceruloplasmin	Copper-carrying protein crucial for iron metabolism.	Low levels are diagnostic of Wilson's disease.	Wilson's disease, chronic liver disease affecting copper metabolism.	Diagnostic and monitoring tool for Wilson's disease and copper metabolism disorders.	Screening and diagnosis of Wilson's disease in suspected cases.

Clinical Applications of Enzymatic and Protein Markers

Enzymatic and protein markers play pivotal roles in the clinical setting, particularly in the diagnosis, management, and monitoring of liver diseases. Their applications span from initial diagnosis to detailed prognostication and therapeutic monitoring.

Diagnostic Tools and Techniques

Initial Screening and Diagnosis

- **Enzymes such as ALT and AST:** Used to detect liver damage. Elevated levels can indicate acute liver injury or chronic liver disease.
- **Proteins like AFP:** Serve as biomarkers for hepatocellular carcinoma (HCC). High levels can prompt further diagnostic imaging and biopsy.

Differentiating Liver Diseases

- **GGT and ALP:** Useful in distinguishing between hepatic and bone disease when ALP is elevated, as GGT is more specific to the liver.
- **CRP:** Helps differentiate inflammatory from non-inflammatory liver diseases due to its sensitivity to inflammation.

Case Studies and Clinical Evidence

Hepatitis Management

- Elevated ALT and AST levels are often seen in viral hepatitis. Monitoring these enzymes helps assess the severity of infection and response to antiviral therapy.

Cirrhosis Monitoring

- **Albumin and prothrombin time:** Important for assessing liver synthetic function and for staging cirrhosis using the Child-Pugh score. This score helps determine prognosis and appropriate management strategies.

Monitoring Therapeutic Efficacy

Following Treatment Response in HCC

- **AFP:** A decrease in AFP levels after treatment (e.g., resection, chemotherapy) suggests a good response, whereas increasing levels may indicate recurrence.

Post-Transplant Monitoring

- **Liver enzymes:** Regular monitoring post-liver transplant helps quickly identify complications such as graft rejection or infection.

Prognostic Value in Clinical Outcomes

Predicting Surgical Outcomes

- **Pre-operative levels of bilirubin, albumin, and INR:** Can predict surgical risks and post-operative liver function in patients undergoing liver surgery.

Guiding Clinical Decisions

- The integration of enzyme and protein levels into clinical algorithms (e.g., MELD score) aids in critical decisions like prioritization for liver transplantation.

Challenges and Limitations

Despite the valuable insights provided by hepatic enzymes and protein markers in liver disease management, several challenges and limitations affect their clinical utility.

Table 3 *(Challenges and Limitations.)*

Challenge Category	Specific Issue	Impact on Diagnosis/Management	Example Markers Affected	Potential Solution or Consideration
Specificity Issues	Non-specific elevations	Complicates diagnosis; may lead to misdiagnosis	AST (also found in muscles)	Use in conjunction with specific clinical assessments and other specific markers
Variability	Inter-individual differences	Could lead to over- or underestimation of liver disease severity	ALT, Albumin	Develop personalized reference ranges based on demographics and health background
Sensitivity Limitations	Inadequate early disease detection	Delay in diagnosis until disease progression	AFP (low sensitivity in early HCC)	Research and validate more sensitive biomarkers for early detection
Dynamic Changes	Fluctuations due to external factors	Makes consistent monitoring challenging	All liver enzymes (e.g., influenced by diet, medication)	Standardize testing conditions and timing relative to external factors
Technological Constraints	Variations in lab standards	Results inconsistency across different facilities	All markers	Implement standardized protocols and calibration across testing sites
Access Issues	Limited testing availability in some regions	Delays in diagnosis and management, especially in remote areas	All markers, especially advanced protein assays	Improve infrastructure and access to portable, cost-effective testing technologies

Interpretational Complexity	Need for comprehensive evaluation	Risk of misinterpretation if considered in isolation	All enzymes and proteins	Training in integrated diagnostics and decision support systems

Table 4 *(Future Directions in Liver Disease Management: Advancements and Considerations.)*

Focus Area	Key Development	Potential Impact	Example Applications	Considerations
Enhanced Biomarker Discovery	Identification of novel biomarkers with enhanced specificity and sensitivity.	Improved early detection and accurate monitoring of liver diseases.	Genetic markers, microRNA panels.	Rigorous validation and standardization of new biomarkers.
Advanced Diagnostic Technologies	Non-invasive imaging modalities for detailed liver assessment.	Enhanced diagnostic capabilities without invasive procedures.	Elastography, contrast-enhanced ultrasound.	Training healthcare professionals for optimal utilization of advanced imaging techniques.
Integration of Artificial Intelligence	AI-driven analysis of biomarker patterns for precise diagnosis and prognosis.	Enhanced accuracy in disease prediction and treatment planning.	Machine learning models, digital health platforms.	Ethical use of patient data and ensuring algorithm transparency.
Personalized Medicine Approaches	Tailoring treatment strategies based on individual biomarker profiles.	Optimized therapeutic outcomes and minimized side effects.	Individualized drug regimens, precision medicine in transplantation.	Consideration of patient preferences and cost-effectiveness of personalized treatments.
Regulatory and Ethical Considerations	Establishing international standards for biomarker testing and ethical use of genetic information.	Ensuring consistency, reliability, and ethical handling of biomarker data.	Standardization of testing protocols, ethical guidelines for genetic data use.	Collaboration among regulatory bodies and healthcare organizations for global standards implementation.

CONCLUSION

In conclusion, the future of liver disease management is characterized by innovation, integration of cutting-edge technologies, and a commitment to personalized, patient-centric care. By embracing these advancements and addressing the associated challenges, healthcare professionals can enhance their

ability to diagnose, treat, and monitor liver diseases more effectively, ultimately improving patient outcomes and quality of life.

REFERENCES

1. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38 Suppl 1:2-6.
2. Wazir H, Abid M, Essani B, Saeed H, Ahmad Khan M, Nasrullah F, et al. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. Cureus. 2023;15(12): e49920.
3. Al-Karawi AS, Abid FM, Mustafa A, Abdulla M. Revealing the Urinary Microbiota in Prostate Cancer: A Comprehensive Review Unveiling Insights into Pathogenesis and Clinical Application. Al-Salam Journal for Medical Science. 2024;3(1):45-54.
4. Mohammed AA, Mahmoud HQ, Mhana RS. ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF BREAST CANCER: A SYSTEMATIC REVIEW. World. 2023;2(6).
5. Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147(4):765-83. e4.
6. Satué K, Miguel-Pastor L, Chicharro D, Gardón JC. Hepatic Enzyme Profile in Horses. Animals (Basel). 2022;12(7).
7. Alajeeli FS, Al-Karawi AS, Ali MM. The Immunological Significance of Medicinal Plants in Disease Control and Prevention in Humans. Al-Salam Journal for Medical Science. 2023;2(2):13-9.
8. Asaad LA, Al-Shimary AA, AL-Azzawi MA, Al-Karawi AS, Rasool KH. The Relationship between Renal Impairment and Specific Laboratory Markers: A Comprehensive Investigation Focusing on Athletes. Journal for ReAttach Therapy and Developmental Diversities. 2023;6(8s):452-8.
9. Ahmed MH, Karkush SI, Ali SA, Mohammed AA. Phytochemicals: a new arsenal in drug discovery. International Journal of Medical Science and Dental Health. 2024;10(01):29-44.
10. Lala V, Zubair M, Minter D. Liver function tests. StatPearls. 2023.
11. Sookoian S, Pirola CJ. Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome. World J Gastroenterol. 2012;18(29):3775-81.
12. Melkonian EA, Asuka E, Schury MP. Physiology, gluconeogenesis. 2019.
13. Grant DM. Detoxification pathways in the liver. J Inherit Metab Dis. 1991;14(4):421-30.
14. Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021;13(11):1688-98.
15. Peng L, Gao ZL, Wang YM, He DM, Zhao JM, Bai XF, et al. Clinical Manifestations and Laboratory Tests of AECHB and Severe Hepatitis (Liver Failure): Acute Exacerbation of Chronic Hepatitis B. 2019 May 21:1-89. doi: 10.1007/978-94-024-1603-9_1.
16. Bernardi M, Maggioli C, Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care. 2012;16(2):211.
17. Al-Azzawi MA, Maftool AJ, Al-Shimary AA, Mohammed AA. A Comprehensive Review of Vitamin D3: Metabolism, Functions, and Clinical Implications. International Journal of Medical Science and Dental Health. 2023;9(12):37-46.

18. Głowska-Ciemny J, Szymanski M, Kuszerska A, Rzepka R, von Kaisenberg CS, Kocyłowski R. Role of Alpha-Fetoprotein (AFP) in Diagnosing Childhood Cancers and Genetic-Related Chronic Diseases. Cancers (Basel). 2023;15(17).
19. Islam R, Kundu S, Jha SB, Rivera AP, Flores Monar GV, Islam H, et al. Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management. Cureus. 2022;14(4): e23785.
20. Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol. 2018; 9:754.
21. Roeser HP, Lee GR, Nacht S, Cartwright GE. The role of ceruloplasmin in iron metabolism. J Clin Invest. 1970;49(12):2408-17.